Statistical Measurement [Domain] Statistical Measurement [Domain] Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Revenues recognized for performance obligations satisfied in previous periods Contract with Customer, Performance Obligation Satisfied in Previous Period Tabular List, Table Tabular List [Table Text Block] Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Products Derived From Other Compounds Products Derived From Other Compounds [Member] Products Derived From Other Compounds [Member] Ipsen Pharma SAS Ipsen [Member] Ipsen [Member] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable Share-based Payment Arrangement Share-Based Payment Arrangement [Member] License revenues License revenues License revenues License [Member] Stock transactions associated with taxes withheld on equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (in dollars per share) Net income per share — basic Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Total Inventory, Gross Commercial paper Commercial Paper [Member] REVENUES Revenue from Contract with Customer [Text Block] Collaborative arrangement, maximum aggregate development milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments Schedule of Collaborative Revenues Under Collaboration and License Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Selling, general, and administrative Selling, General And Administrative Expense, Excluding Separate Accounts Selling, General And Administrative Expense, Excluding Separate Accounts Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Contract liabilities: Accounts Payable and Accrued Liabilities [Abstract] Adjustment to Compensation, Amount Adjustment to Compensation Amount Percent of total revenues Concentration Risk, Percentage Basis of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Stock options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Non-current portion included in other non-current assets Other Long-term Assets [Member] Other Long-term Assets [Member] Accrued collaboration liabilities Accrued Collaboration Liability, Current Accrued Collaboration Liability, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Insider Trading Policies and Procedures [Line Items] Total stock-based compensation Total stock-based compensation Share-Based Payment Arrangement, Expense Rebates Allowance For Product Rebates [Member] Allowance For Product Rebates [Member] Shares authorized (in shares) Common Stock, Shares Authorized Current assets: Assets, Current [Abstract] Total liabilities and stockholders’ equity Liabilities and Equity Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total Debt Securities, Available-for-Sale, Unrealized Loss Position Collaborative arrangement, maximum aggregate regulatory milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Shell Company Entity Shell Company Common stock Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Other non-current liabilities Other Liabilities, Noncurrent Collaboration revenues Collaboration revenues Collaboration [Member] Collaboration [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Maturing in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Schedule of Allocated Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Litigation Case [Domain] Litigation Case [Domain] Schedule of Investments by Security Type Unrealized Gain (Loss) on Investments [Table Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Award Type [Axis] Award Type [Axis] Non-current portion Contract with Customer, Liability, Noncurrent Total assets Assets Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Issuance of common stock under the equity incentive plans and stock purchase plan (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, City or Town Entity Address, City or Town ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Other segment items Segment Reporting, Other Segment Item, Amount Concentration Risk Type [Axis] Concentration Risk Type [Axis] INVENTORY Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Less: Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Reduction in share reserve after stock option or stock appreciation award (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award Share-based Compensation Arrangement by Share-based Payment Award, Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Discounts and allowances Product, Sales Discounts And Allowances [Member] Product, Sales Discounts And Allowances [Member] Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Other Customer Credits/Fees and Co-pay Assistance Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member] Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Drug discovery Drug Discovery Costs Drug Discovery Costs Shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Plan Name [Axis] Plan Name [Axis] PEO PEO [Member] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] October 2025 Repurchase Program October 2025 Repurchase Program [Member] October 2025 Repurchase Program U.S. UNITED STATES Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Research Collaborations, In-Licensing Arrangements and Other Business Development Activities Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member] Research Collaborations, In-Licensing Arrangements and Other Business Development Activities Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis Affiliates of Cencora, Inc. Affiliates Of Cencora, Inc [Member] Affiliates Of Cencora, Inc. (formerly Amerisource Bergen Corporation) [Member] Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Affiliates of McKesson Corporation Affiliates of McKesson Corporation [Member] Affiliates of McKesson Corporation [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Provision for income taxes Income Tax Expense (Benefit) In an Unrealized Loss Position 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Purchases of marketable securities Payments to Acquire Marketable Securities Shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Debt securities available-for-sale: Debt Securities, Available-for-Sale [Abstract] Customer Concentration Risk Customer Concentration Risk [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Derivative notional amount Derivative, Notional Amount Affiliates of Optum Specialty Pharmacy Affiliates of Optum Specialty Pharmacy [Member] Affiliates of Optum Specialty Pharmacy [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amended And Restated 2017 Equity Incentive Plan Amended And Restated 2017 Equity Incentive Plan [Member] Amended And Restated 2017 Equity Incentive Plan Fair Value Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-cash lease expense Noncash Lease Expense Noncash Lease Expense Gross Unrealized Gains Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Number of awards outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Other Assets and Other Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Options, unrecognized stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Interest receivable Interest Receivable SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Subsequent Event [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Goodwill Goodwill Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Money market funds Money market funds Money Market Funds [Member] Equity Components [Axis] Equity Components [Axis] Fair Value Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk [Table] Concentration Risk [Table] Net product revenues Net product revenues Net product revenues Product [Member] Number of reportable segments Number of Reportable Segments Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Inventory [Line Items] Inventory [Line Items] U.S. Treasury and government-sponsored enterprises U.S. Treasury and government-sponsored enterprises US Treasury and Government [Member] Entity Address, State or Province Entity Address, State or Province Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Derivative Instrument [Axis] Derivative Instrument [Axis] Individual: Individual [Axis] Vesting [Axis] Vesting [Axis] Numerator: Earnings Per Share Reconciliation [Abstract] Research and development Research and Development Expense [Member] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Current portion included in inventory Inventories [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Accrued compensation and benefits Accrued Employee Benefits, Current Effective income tax rate (as percent) Effective Income Tax Rate Reconciliation, Percent Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] Revenues Revenue from Contract with Customer [Policy Text Block] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Non-current marketable securities Marketable Securities, Noncurrent Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Selling, general and administrative Selling, General and Administrative Expense MSN II ANDA MSN II ANDA [Member] MSN II ANDA Cumulative net sales milestone Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold Balance at December 31, 2025 Balance at March 31, 2026 SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Deferred tax assets, net Deferred Income Tax Assets, Net Repurchases of common stock Stock Repurchased During Period, Value Depreciation and amortization Depreciation, Depletion and Amortization Rebates and fees due to customers Customer Refund Liability, Current Ipsen And Takeda Collaborations Ipsen And Takeda Collaborations [Member] Ipsen And Takeda Collaborations Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Revenue from contract with customer, regulatory milestone Revenue From Contract With Customer, Regulatory Milestone Revenue From Contract With Customer, Regulatory Milestone Finished goods Inventory, Finished Goods, Gross Collaborative Arrangement with Ipsen Collaborative Arrangement with Ipsen [Member] Collaborative Arrangement with Ipsen [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost Arrangement Duration Trading Arrangement Duration COMETRIQ Cometriq [Member] Cometriq [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Gross Unrealized Losses Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss Current portion Contract with Customer, Liability, Current Segments [Axis] Segments [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Resulting From Discovery Efforts Resulting From Discovery Efforts [Member] Resulting From Discovery Efforts [Member] Weighted average grant date fair value, awarded (in dollars per share) Share Price Inventory, Current [Table] Inventory, Current [Table] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Europe Europe [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Text Block] Repurchases of common stock (in shares) Stock Repurchased and Retired During Period, Shares ASSETS Assets [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Preferred stock Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Vesting [Domain] Vesting [Domain] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Vesting award percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Entity Address, Address Line One Entity Address, Address Line One Gross product revenues Product, Gross [Member] Product, Gross [Member] Research and development Research and Development Expense Accumulated Other Comprehensive income (loss) AOCI Attributable to Parent [Member] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Gross Unrealized Gains Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain Work in process Inventory, Work in Process, Gross Royalty expense Royalty Expense Cardinal Health, Inc. Cardinal Health [Member] Cardinal Health Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Municipal bonds Municipal Bonds [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Number of awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total operating expenses Costs and Expenses Document Quarterly Report Document Quarterly Report In an Unrealized Loss Position Less than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Total financial assets carried at fair value Assets, Fair Value Disclosure Number of investments in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Number of business segments Number of Operating Segments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Weighted average grant date fair value, awarded (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaboration services revenues Collaboration services revenues Collaboration services revenues Service [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Maximum potential to vest Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract] Issuance of common stock under equity incentive plan and stock purchase plan Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Percent of royalty on net sale Collaboration Agreement, Percent Of Royalty On Net Sale Collaboration Agreement, Percent Of Royalty On Net Sale Accounts Receivable Accounts Receivable [Member] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Contract revenue recognized, including revenue from deferred revenue beginning balance Contract With Customer, Liability, Including New Contract Revenue, Recognized Contract With Customer, Liability, Including New Contract Revenue, Recognized Number of products that entered in the commercial marketplace Number Of Products In Commercial Market Number Of Products In Commercial Market Interest income Interest income Interest Income, Other Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Collaborative Arrangements with Glaxo Smith Kline Collaborative Arrangements with Glaxo Smith Kline [Member] Collaborative Arrangements with Glaxo Smith Kline Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] Current period Valuation Allowances And Reserves, Additions For Sales In Current Period Valuation Allowances And Reserves, Additions For Sales In Current Period Provision related to sales made in: Valuation Allowances And Reserves, Additions To Provision [Abstract] Valuation Allowances And Reserves, Additions To Provision [Abstract] Final Tier Final Tier [Member] Final Tier[Member] Equity Awards Adjustments Equity Awards Adjustments [Member] Other, net Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Prior periods Valuation Allowances And Reserves, Additions For Sales In Prior Period Valuation Allowances And Reserves, Additions For Sales In Prior Period Compensation Amount Outstanding Recovery Compensation Amount Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Certificates of deposit Certificates of deposit Certificates of Deposit [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Share Repurchase Program [Axis] Share Repurchase Program [Axis] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Weighted-average common shares outstanding: Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Employee stock purchase plan Employee Stock [Member] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Revenues: Revenues [Abstract] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Net unrealized gains (losses) on available-for-sale debt securities, tax impact OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Financial Instruments [Domain] Financial Instruments [Domain] Litigation Case [Axis] Litigation Case [Axis] Segments [Domain] Segments [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Performance stock units Performance Shares [Member] Royalty Tier [Domain] Royalty Tier [Domain] Royalty Tier [Domain] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Right-of-use assets and other non-current assets Operating Lease, Right-Of-Use Asset And Other Non-Current Assets Operating Lease, Right-Of-Use Asset And Other Non-Current Assets Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Inventory Increase (Decrease) in Inventories Inventory Inventory, Net Minimum Minimum [Member] Company Selected Measure Name Company Selected Measure Name Development Development Expenses Development Expenses Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 253,701 and 262,483 at March 31, 2026, and December 31, 2025, respectively Common Stock, Value, Issued COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Diluted (in shares) Weighted-average common shares outstanding — diluted Weighted Average Number of Shares Outstanding, Diluted Segment Reporting Segment Reporting, Policy [Policy Text Block] Commitments and contingencies (Note 11) Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Schedule of Revenues Disaggregated by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Document Transition Report Document Transition Report Maturing after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Schedule of Concentration Risks Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Underlying Securities Award Underlying Securities Amount Concentration Risk [Line Items] Concentration Risk [Line Items] Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] PROVISION FOR INCOME TAXES Income Tax Disclosure [Text Block] CABOMETYX Cabometyx [Member] Cabometyx [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from contract with customer, commercial sales milestone Revenue From Contract With Customer, Commercial Sales Milestone Revenue From Contract With Customer, Commercial Sales Milestone Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Reduction in share reserve after all other awards (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards Share-based Compensation Arrangement by Share-based Payment Award, Reduction of Number of Shares in Share Reserve Document Type Document Type Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract] NET INCOME PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Additional paid-in-capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Number of contract Derivative, Number of Instruments Held Derivative Contract [Domain] Derivative Contract [Domain] Revenue Revenue from Contract with Customer Benchmark [Member] Total revenues Revenues Net product revenues Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property, equipment and other, net Payments to Acquire Property, Plant, and Equipment Accrued clinical trial liabilities Accrued Clinical Liabilities, Current Accrued Clinical Liabilities, Current Name Forgone Recovery, Individual Name Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Proceeds from issuance of common stock under the equity incentive plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Acquired in-process research and development technology Payments to Acquire in Process Research and Development Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Derivative term of contract Derivative, Term of Contract Marketable securities Marketable Securities, Current Chargebacks, Discounts for Prompt Payment and Other Chargebacks And Discounts For Prompt Payment [Member] Chargebacks And Discounts For Prompt Payment [Member] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Schedule of Segment and Consolidated Net Income, Including Significant Segment Expenses Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Geographical [Axis] Geographical [Axis] Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Level 1 Fair Value, Inputs, Level 1 [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Accrued collaboration liabilities Increase (Decrease) in Accrued Liabilities Diluted (in dollars per share) Net income per share — diluted Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Net income per share: Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Collaborative Arrangement with Takeda Collaborative Arrangement with Takeda [Member] Collaborative Arrangement with Takeda [Member] Asset Acquisition [Table] Asset Acquisition [Table] Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Repurchases of common stock Stock Repurchased and Retired During Period, Value Collaborative Arrangements with Royalty Pharma Collaborative Arrangements with Royalty Pharma [Member] Collaborative Arrangements with Royalty Pharma Corporate bonds Corporate bonds Corporate Bond Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $1,147 and $(983), respectively OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Acquired in-process research and development technology Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Fiscal Period Fiscal Period, Policy [Policy Text Block] Segment and consolidated net income Net income Net income Net Income (Loss) Attributable to Parent Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Expiration Date Trading Arrangement Expiration Date Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payments and customer credits issued SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Shares authorized (in shares) Preferred Stock, Shares Authorized Payments for repurchases of common stock Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Trade receivables, net Increase (Decrease) in Accounts Receivable CASH AND MARKETABLE SECURITIES Investment in Debt and Equity Instruments and Cash and Cash Equivalent [Text Block] Entity Current Reporting Status Entity Current Reporting Status Number of lawsuits Loss Contingency, Number Of Lawsuits Consolidated Loss Contingency, Number Of Lawsuits Consolidated Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Gross Unrealized Losses Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Income from operations Operating Income (Loss) Japan JAPAN Accumulated deficit Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Foreign Exchange Forward Foreign Exchange Forward [Member] In an Unrealized Loss Position 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Current Fiscal Year End Date Current Fiscal Year End Date Subsequent Event Type [Domain] Subsequent Event Type [Domain] In an Unrealized Loss Position Less than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other income (expenses), net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Adjustments to reconcile net income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES Collaborative Arrangement Disclosure [Text Block] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash Cash [Member] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Trade receivables, net Receivables, Net, Current Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Total contract liabilities Contract with Customer, Liability Proceeds from maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Anti-dilutive securities and contingently issuable shares excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Income before income taxes Income (Loss) Attributable to Parent, before Tax Termination Date Trading Arrangement Termination Date Net cash used in financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Reportable Segment Reportable Segment [Member] Reportable Segment Schedule of Fair Value of Financial Assets Measured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted-average common shares outstanding — basic Weighted Average Number of Shares Outstanding, Basic Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Stock repurchase program, remaining authorized repurchase amount Share Repurchase Program, Remaining Authorized, Amount Cost of goods sold Cost of goods sold Cost of Product and Service Sold Schedule of Computation of Basic and Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Royalty Tier [Axis] Royalty Tier [Axis] royalty tier [Axis] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Percent of royalty on net sale Percent of royalty on net sale Percent of royalty on net sale. Accredo Health, Incorporated Accredo Health, Incorporated [Member] Accredo Health, Incorporated Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Affiliates of CVS Health Corporation Affiliates of CVS Health Corporation [Member] Affiliates of CVS Health Corporation [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Par value (in dollars per share) Common Stock, Par or Stated Value Per Share Shares issued (in shares) Common Stock, Shares, Issued Use of Estimates Use of Estimates, Policy [Policy Text Block] Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Loss Contingencies [Line Items] Loss Contingencies [Line Items] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Raw materials Inventory, Raw Materials, Gross Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Repurchases of common stock (in shares) Stock Repurchased During Period, Shares Operating expenses: Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other current liabilities Other Liabilities, Current 2026 TSR-based RSUs TSR-Based Restricted Stock Units [Member] TSR-Based Restricted Stock Units Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Common Stock Common Stock [Member] Fair Value Total debt securities available-for-sale Total debt securities available-for-sale Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Net decrease in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Dilutive securities Weighted Average Number of Shares Outstanding, Diluted, Adjustment